| An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations HE Silber, PM Jauslin, N Frey, R Gieschke, USH Simonsson, ... The Journal of Clinical Pharmacology 47 (9), 1159-1171, 2007 | 150 | 2007 |
| An integrated glucose‐insulin model to describe oral glucose tolerance test data in type 2 diabetics PM Jauslin, HE Silber, N Frey, R Gieschke, USH Simonsson, K Jorga, ... The Journal of Clinical Pharmacology 47 (10), 1244-1255, 2007 | 105 | 2007 |
| Modeling of 24‐hour glucose and insulin profiles of patients with type 2 diabetes PM Jauslin, N Frey, MO Karlsson The Journal of Clinical Pharmacology 51 (2), 153-164, 2011 | 74 | 2011 |
| An integrated model for the glucose‐insulin system HE Silber, PM Jauslin, N Frey, MO Karlsson Basic & clinical pharmacology & toxicology 106 (3), 189-194, 2010 | 52 | 2010 |
| Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose‐insulin model PM Jauslin, MO Karlsson, N Frey The Journal of Clinical Pharmacology 52 (12), 1861-1871, 2012 | 42 | 2012 |
| Population-Pharmacokinetic modeling of tildrakizumab (MK-3222), an anti-interleukin-23-p19 monoclonal antibody, in healthy volunteers and subjects with psoriasis P Jauslin, P Kulkarni, H Li, S Vatakuti, A Hussain, L Wenning, T Kerbusch Clinical Pharmacokinetics 58, 1059-1068, 2019 | 9 | 2019 |
| Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling DD Marathe, PM Jauslin, HJ Kleijn, C de Miranda Silva, A Chain, ... CPT: Pharmacometrics & Systems Pharmacology 12 (10), 1499-1510, 2023 | 6 | 2023 |
| Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: pooled analysis of 3 randomised controlled trials T Kerbusch, H Li, R Wada, PM Jauslin, L Wenning British Journal of Clinical Pharmacology 86 (9), 1795-1806, 2020 | 6 | 2020 |
| Mechanism-based modeling of the glucose-insulin regulation during clinical provocation experiments P Jauslin-Stetina Acta Universitatis Upsaliensis, 2008 | 4 | 2008 |
| Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy MA Tortorici, T Yuraszeck, D Cornblath, V Bril, HP Hartung, G Sobue, ... CPT: Pharmacometrics & Systems Pharmacology 10 (8), 839-850, 2021 | 3 | 2021 |
| Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study JZ He, V Duval, P Jauslin, A Gonçalves, A Abegesah, C Fan, KS Lim, ... Clinical Pharmacology & Therapeutics 114 (6), 1375-1386, 2023 | 2 | 2023 |
| Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis. N Wagner, L Loprete, V Duval, P Jauslin, K Benkali, JI Silverberg, ... Journal of Drugs in Dermatology: JDD 22 (10), 1017-1020, 2023 | 2 | 2023 |
| Population pharmacokinetic modelling of tildrakizumab (MK-3222), an anti-interleukin-23-p19 monoclonal antibody, in healthy volunteers and patients with psoriasis P Jauslin, P Kulkarni, R Wada, S VataKuti, A Hussain, L Wenning, ... BRITISH JOURNAL OF DERMATOLOGY 177 (5), E255-E255, 2017 | 1 | 2017 |
| Comparison of post-prandial glucose control by two GLP-1 receptor agonists (lixisenatide and liraglutide) in type 2 diabetes P Jauslin, M Dubar, B Sebastien, C Laveille, PO Gisleskog Poster presented at the Population Approach Group Meeting in Alicante, Spain, 2014 | 1 | 2014 |
| Exposure–Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling DD Marathe, PM Jauslin, H Jan Kleijn, C De Miranda Silva, A Chain, ... The Journal of Clinical Pharmacology 64 (10), 1246-1258, 2024 | | 2024 |
| POPULATION-PK (POPPK) AND EXPOSURE-RESPONSE (ER) ANALYSES FOR BELZUTIFAN TO INFORM DOSING CONSIDERATIONS AND LABELING. D Marathe, P Jauslin, H Kleijn, C Silva, D Miranda, A Abraham, E Kauh, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S35-S35, 2022 | | 2022 |
| FC07. 1.4 USING SYSTEMS BIOLOGY TO DEVELOP BETTER ONCOLOGY DRUGS MO Karlsson, H Silber, P Jauslin, N Frey | | |
| Population Approach Group Europe Population Approach Group Europe P Jauslin | | |
| Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis P Jauslin, A Largajolli, E Schindler, T Saito, L Loprete, N Wagner, V Duval | | |
| 2025 Thessaloniki, Greece P Jauslin, M Dubar, B Sebastien, C Laveille, PO Gisleskog | | |
